​

Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Halozyme Therapeutics Ownership Summary

Halozyme Therapeutics is owned by 106.90% institutional investors, 1.17% insiders. Blackrock is the largest institutional shareholder, holding 13.88% of HALO shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.43% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockHalozyme Therapeutics106.90%1.17%-8.07%
SectorHealthcare Stocks 487.91%11.08%-398.99%
IndustryBiotech Stocks 307.16%11.11%-218.27%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock17.62M13.88%$922.58M
Blackrock funding, inc. /de13.20M10.88%$686.67M
Vanguard group13.28M10.47%$635.00M
Dld asset management, lp12.50M10.30%$14.31M
State street5.81M4.58%$304.43M
Snyder capital management l p3.40M2.80%$176.75M
Alliancebernstein3.07M2.42%$146.70M
Geode capital management3.06M2.42%$146.53M
Macquarie group2.91M2.29%$138.91M
Arrowstreet capital, limited partnership2.54M2.09%$132.19M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Koa wealth management86.64K4.71%$6.35M
Snyder capital management l p3.40M3.76%$176.75M
Cutter capital management, lp120.00K3.33%$7.66M
Steamboat capital partners171.50K2.54%$8.92M
Bernzott capital advisors69.25K2.40%$5.08M
South street advisors241.27K1.86%$12.55M
2xideas184.55K1.65%$9.60M
Unified investment management21.88K1.60%$1.60M
Renaissance group478.74K1.32%$35.11M
Future fund55.69K1.29%$2.90M

Top Buyers

HolderShares% AssetsChange
Dld asset management, lp12.50M0.81%12.50M
Arrowstreet capital, limited partnership2.54M0.09%1.43M
Norges bank1.26M0.01%1.26M
Federated hermes1.45M0.19%1.08M
Qube research986.07K0.05%986.07K

Top Sellers

HolderShares% AssetsChange
Blackrock funding, inc. /de13.20M0.01%-3.89M
Handelsbanken fonder ab516.47K0.09%-1.45M
Frontier capital management---1.27M
American century companies132.53K0.00%-762.89K
State street5.81M0.01%-673.10K

New Positions

HolderShares% AssetsChangeValue
Dld asset management, lp12.50M0.81%12.50M$14.31M
Norges bank1.26M0.01%1.26M$60.05M
Renaissance group478.74K1.32%478.74K$35.11M
Weiss asset management lp211.25K0.13%211.25K$10.99M
Twinbeech capital lp198.07K0.23%198.07K$10.30M

Sold Out

HolderChange
Harbor investment advisory-4.00
Raleigh capital management-6.00
Van hulzen asset management-8.00
Southstate-9.00
Bare financial services-10.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025552-1.08%129,712,8686.64%1061.10%263-16.51%21229.27%
Mar 31, 202515-97.10%5,085,362-95.89%40.04%6-97.75%4-97.75%
Dec 31, 2024292-43.41%70,690,093-43.61%550.57%130-52.38%114-30.91%
Sep 30, 20245109.68%124,779,1382.05%981.06%27011.57%1653.77%
Jun 30, 20244589.05%122,203,811-0.27%961.03%2378.22%15811.27%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Mid-Cap ETF4.01M3.43%-
Vanguard Total Stock Mkt Idx Inv3.87M3.31%-94.98K
Vanguard US Total Market Shares ETF4.03M3.27%3.36K
Vanguard Small Cap Index2.99M2.56%-20.32K
iShares Russell 2000 ETF3.13M2.54%-
Aviva Investors GlConvtAbsRet I USD Acc2.74M2.16%2.74M
SPDR® S&P Biotech ETF2.18M1.86%4.86K
Vanguard Small Cap Growth Index Inv1.69M1.44%-1.74K
Delaware Small Cap Core I1.74M1.37%-10.77K
Vanguard Institutional Extnd Mkt Idx Tr1.32M1.13%-572.80K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 03, 2025Torley Helen PRESIDENT AND CEOSell$162.98K
Oct 01, 2025Torley Helen PRESIDENT AND CEOSell$879.15K
Oct 02, 2025Torley Helen PRESIDENT AND CEOSell$465.36K
Oct 03, 2025Torley Helen PRESIDENT AND CEOSell$974.70K
Oct 02, 2025Torley Helen PRESIDENT AND CEOSell$727.04K

Insider Transactions Trends

DateBuySell
2027 Q1--
2026 Q1--
2025 Q4-13
2025 Q3-27
2025 Q2-7

HALO Ownership FAQ

Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 106.90%, followed by 1.17% insiders and -8.07% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 307.16%, which Halozyme Therapeutics falls below.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Blackrock (17.62M shares, 13.88%), Blackrock funding, inc. /de (13.2M shares, 10.88%), and Vanguard group (13.28M shares, 10.47%). Together, they hold 35.23% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Koa wealth management is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.71% of its assets in 86.64K Halozyme Therapeutics shares, valued at 6.35M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.43% of its total shares outstanding invested in 4.01M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools